# US 2025/0085282 A1 · Method for detecting anti-sars-cov-2 spike (s) immunoglobulins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0085282 A1
- Document ID: US20250085282A1
- Status: Published application
- Kind: A1
- Application number: 18/882,452
- Filed: 2024-09-11
- Published: 2025-03-13
- Earliest claimed: 2023-09-11
- Assignees: Novavax, Inc.
- Applicants: Novavax, Inc.
- Inventors: Joyce S. PLESTED; Raj KALKERI
- Web page: https://patentgrep.com/patent/US20250085282A1

## CPC

- G01N 33/56983: {Viruses}
- G01N 33/6854: {Immunoglobulins}
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are methods for detecting if a biological sample (e.g., serum, blood, plasma) contains antibodies against SARS-CoV-2 S glycoproteins comprising: (i) providing a surface coated with a SARS-CoV-2 S glycoprotein; (ii) exposing the surface to the biological sample; (iii) exposing the surface to a secondary antibody; and (iv) detecting the secondary antibody that is bound to the surface; wherein the biological sample contains antibodies that bind to the SARS-CoV-2 S glycoprotein if secondary antibody is detected.

## Claims

### Claim 1

A method for determining if a biological sample contains antibodies that bind to the SARS-CoV-2 Spike (S) glycoprotein, comprising:
(i) providing a surface coated with a SARS-CoV-2 S glycoprotein;
(ii) exposing the surface to the biological sample;
(iii) exposing the surface to a secondary antibody; and
(iv) detecting the secondary antibody that is bound to the surface;
wherein the biological sample contains antibodies that bind to the SARS-CoV-2 S glycoprotein if the secondary antibody is detected.

### Claim 2 (depends on 1)

The method of claim 1, wherein the SARS-CoV-2 S glycoprotein has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a polypeptide of any one of SEQ ID NOS: 2, 4, 38, 41, 44, 48, 51, 54, 58, 61, 63, 65, 67, 73, 75, 78, 79, 82, 83, 85, 106, 108, 89, and 110, 112-115, 132, 133, 114, 138, 141, 144, 147, 151, 153, 156, 158, 174, 175, 176, 181-184, 186, 188, 190, 195, 217-228, 233-236, 243, 255-264, 273-280, 283, 284, 287, 288, 291, 292, and 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 236, 328, 329, 330, 331, 332 and 333.

### Claim 3 (depends on 1)

The method of claim 1, wherein the SARS-CoV-2 S glycoprotein has an inactive furin cleavage site.

### Claim 4 (depends on 3)

The method of claim 3, wherein the SARS-CoV-2 S glycoprotein has an inactive furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7).

### Claim 5 (depends on 1)

The method of claim 1, wherein amino acids 973 and 974 of the SARS-CoV-2 S glycoprotein are proline, as compared to a wild-type SARS-CoV-2 S glycoprotein having the amino acid sequence of SEQ ID NO: 2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibodies that bind to the SARS-CoV-2 S glycoprotein are IgG1 or IgG2 or IgG3 or IgG4.

### Claim 7 (depends on 6)

The method of claim 6, wherein the antibodies that bind to the SARS-CoV-2 S glycoprotein are IgG3.

### Claim 8 (depends on 6)

The method of claim 6, wherein the antibodies that bind to the SARS-CoV-2 S glycoprotein are IgG4.

### Claim 9 (depends on 1)

The method of claim 1, wherein the secondary antibody is selected from the group consisting of an anti-human IgG antibody, an anti-human IgG1 antibody, an anti-human IgG2 antibody, an anti-human IgG3 antibody and an anti-human IgG4 antibody.

### Claim 10 (depends on 1)

The method of claim 1, wherein the SARS-CoV-2 S glycoprotein is selected from a SARS-CoV-2 virus or a variant of SARS-CoV-2 or a subvariant of a variant of SARS-CoV-2.

### Claim 11 (depends on 10)

The method of claim 10, wherein the variant of SARS-CoV-2 is a B.1.1.7 SARS-CoV-2 strain; a B.1.351 SARS-CoV-2 strain; a P.1 SARS-CoV-2 strain; a Cal.20C SARS-CoV-2 strain; a B.1.617.2 SARS-CoV-2 strain; a B.1.525 SARS-CoV-2 strain; a B.1.526 SARS-CoV-2 strain; a B.1.617.1 SARS-CoV-2 strain; a C.37 SARS-CoV-2 strain; a B.1.621 SARS-CoV-2 strain; or a B.1.1.529 SARS-CoV-2 strain.

### Claim 12 (depends on 10)

The method of claim 10, wherein the variant of SARS-CoV-2 is a subvariant of a B.1.1.7 SARS-CoV-2 strain; a B.1.351 SARS-CoV-2 strain; a P.1 SARS-CoV-2 strain; a Cal.20C SARS-CoV-2 strain; a B.1.617.2 SARS-CoV-2 strain; a B.1.525 SARS-CoV-2 strain; a B.1.526 SARS-CoV-2 strain; a B.1.617.1 SARS-CoV-2 strain; a C.37 SARS-CoV-2 strain; a B.1.621 SARS-CoV-2 strain; or a B.1.1.529 SARS-CoV-2 strain.

### Claim 13 (depends on 1)

The method of claim 1, wherein the SARS-CoV-2 S glycoprotein has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to any one of SEQ ID NOS: 2, 4, 38, 41, 44, 48, 51, 54, 58, 61, 63, 65, 67, 73, 75, 78, 79, 82, 83, 85, 106, 108, 89, and 110, 112-115, 132, 133, 114, 138, 141, 144, 147, 151, 153, 156, 158, 174, 175, 176, 181-184, 186, 188, 190, 195, 217-228, 233-236, 243, 255-264, 273-280, 283, 284, 287, 288, 291, 292, and 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 236, 328, 329, 330, 331, 332 and 333.

### Claim 14 (depends on 1)

The method of claim 1, wherein the SARS-CoV-2 S glycoprotein has at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to to a SARS-CoV-2 S glycoprotein from a SARS-CoV-2 S omicron variant selected from the group consisting of: BA.1, BA.2.12.1, BA.2, BA.3, BA.4, BA.5, XBB.1.5, XBB.2.3, and XBB.1.16, EG.5.1, JN.1, BQ.1.1, BF.7.

### Claim 15 (depends on 1)

The method of claim 1, wherein the secondary antibody is attached to a tag.

### Claim 16 (depends on 15)

The method of claim 15, wherein the tag is horseradish peroxidase.

### Claim 17 (depends on 1)

The method of claim 1, wherein the biological sample is serum, plasma, blood, saliva, a nasopharyngeal swab, or mucus.

### Claim 18 (depends on 1)

The method of claim 1, wherein the biological sample is from a patient that has previously had COVID-19.

### Claim 19 (depends on 1)

The method of claim 1, wherein the biological sample is from a patient who has been administered an immunogenic composition against a SARS-CoV-2 virus or a variant thereof.

### Claim 20 (depends on 1)

The method of claim 1, wherein the SARS-CoV-2 S glycoprotein includes the transmembrane domain.
